Upcoming EventsMore >>
9:10 a.m. ET
Amgen at Morgan Stanley Global Healthcare Conference
LocationGrand Hyatt
New York, NY US
Recent NewsMore >>
08/28/14Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol
Study Meets Co-Primary Endpoints of LDL Cholesterol Reduction THOUSAND OAKS, Calif., Aug. 28, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 YUKAWA-2 (StudY of LDL-Cholesterol Reduction Using a Monoclonal PCSK9 Antibody in Japanese Patients With Advanced Cardiovascular Risk) study evaluating evolocumab in combination with statin therapy in Japanese patients with high cardiovascular risk and high cholesterol met its co-primary endpoints: the percent reduction from ... 
Printer Friendly Version
08/28/14Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA
Represents First BLA Submission for a PCSK9 Inhibitor THOUSAND OAKS, Calif., Aug. 28, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for evolocumab seeking approval for the treatment of high cholesterol. Evolocumab is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability ... 
Printer Friendly Version
08/27/14FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure
THOUSAND OAKS, Calif., Aug. 27, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the U.S. Food and Drug Administration (FDA) has granted priority review designation for ivabradine for the treatment of chronic heart failure (HF). Ivabradine is an oral drug that inhibits the If current ("funny" current) in the sinoatrial node, the body's cardiac pacemaker.1 Ivabradine works to slow the heart rate without negative effects on myocardial contractility or ventricular repolarization.1 Heart fa... 
Printer Friendly Version
08/19/14Amgen Names Elliott M. Levy, M.D., Senior Vice President, Global Development
THOUSAND OAKS, Calif. (Aug. 19, 2014) – Amgen (NASDAQ:AMGN) today announced that Elliott M. Levy, M.D., has been named senior vice president, Global Development, effective Sept. 8, 2014. Levy comes to Amgen from Bristol-Myers Squibb (BMS), where he most recently served as senior vice president and head, Specialty Development. “Elliott brings a wealth of development and leadership experience to his new role at Amgen,” said Sean E. Harper, M.D., executive vice president of Research and D... 
Printer Friendly Version
What's New
Download Documentation Investor Insights Newsletter - Q2 2014
Download Documentation Q2 2014 Financial Results
Investor Insights Newsletters
Download Documentation Investor Insights Newsletter - Q2 2014
Download Documentation Investor Insights Newsletter - Q1 2014
Download Documentation Investor Insights Newsletter - Q4 2013
Download Documentation Investor Insights Newsletter - Q3 2013

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.